Spyre Therapeutics Chief Medical Officer Sheldon Sloan sold company stock valued at $624,975. The transaction involved shares of the biopharmaceutical firm.
Insider selling can sometimes signal a lack of confidence from company executives in future stock performance, potentially impacting investor sentiment.
Spyre Therapeutics Chief Medical Officer Sheldon Sloan has sold shares of the company's stock. The total value of the transaction amounted to $624,975. This sale represents a notable insider transaction within the biopharmaceutical firm.
Pick the topics you care about. Get only what matters, on your cadence.
The FX Trader. Worrying about Europe and the new Sick Man.home.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.